2MePI

Drug classSerotonin receptor modulator; Serotonin 5-HT_2A receptor weak partial agonist or functional antagonist

ATC code

• None

CAS Number

• 5094-12-2 ^Y

PubChem CID

• 97424

2MePI

Clinical data
Drug class	Serotonin receptor modulator; Serotonin 5-HT2A receptor weak partial agonist or functional antagonist
ATC code	None
Identifiers
IUPAC name 2-methyl-1,3,4,5-tetrahydropyrido[4,3-b]indole
CAS Number	5094-12-2 Y
PubChem CID	97424
ChemSpider	87935
ChEMBL	ChEMBL1984135
CompTox Dashboard (EPA)	DTXSID30198969
Chemical and physical data
Formula	C12H14N2
Molar mass	186.258 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN1CCC2=C(C1)C3=CC=CC=C3N2
InChI InChI=1S/C12H14N2/c1-14-7-6-12-10(8-14)9-4-2-3-5-11(9)13-12/h2-5,13H,6-8H2,1H3 Key:FYHWPFXPFFPQRT-UHFFFAOYSA-N

2MePI, also known as 2-methyl-2,3,4,5-tetrahydro-1H-pyrido[4,3-b]indole, is a serotonin receptor modulator of the pyridoindole (γ-carboline) family.^[1] It is the pyridoindole homologue of the ibogalog (azepinoindole) ibogaminalog (DM-506).^[1]

The drug acts as a weak partial agonist or functional competitive antagonist of the serotonin 5-HT_2A receptor, with an affinity (K_i) of 95 nM, an EC₅₀Tooltip half-maximal effective concentration (E_maxTooltip maximal efficacy) of 533 nM (32%), an apparent IC₅₀Tooltip half-maximal inhibitory concentration of 3,100 to 18,000 nM, and a K_B of 89 to 228 nM.^[1] Compared to ibogaminalog, 2MePi had 5-fold lower affinity, 59-fold lower activational potency, and less than half the activational efficacy at the serotonin 5-HT_2A receptor.^[1] Results were analogous for 8MeO-2MePI against ibogainalog (8MeO-2MePI's ibogalog homologue).^[1] These findings indicate that ibogalogs are the more optimal structural scaffold for serotonin 5-HT_2A receptor agonism.^[1]

2MePI was first described in the scientific literature by Matthias Liechti and colleagues in 2026.^[1]